1.28
price up icon1.59%   0.02
pre-market  Pre-mercato:  1.31   0.03   +2.34%
loading
Precedente Chiudi:
$1.26
Aprire:
$1.28
Volume 24 ore:
1.43M
Relative Volume:
0.61
Capitalizzazione di mercato:
$53.89M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-0.9209
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
+44.00%
1M Prestazione:
-31.91%
6M Prestazione:
-11.11%
1 anno Prestazione:
-18.99%
Intervallo 1D:
Value
$1.21
$1.32
Intervallo di 1 settimana:
Value
$0.88
$1.32
Portata 52W:
Value
$0.6254
$2.75

Milestone Pharmaceuticals Inc Stock (MIST) Company Profile

Name
Nome
Milestone Pharmaceuticals Inc
Name
Telefono
(514) 336-0444
Name
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Name
Dipendente
33
Name
Cinguettio
@MilestonePharma
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
MIST's Discussions on Twitter

Confronta MIST con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MIST
Milestone Pharmaceuticals Inc
1.28 53.89M 0 -59.69M -46.54M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-22 Iniziato Rodman & Renshaw Buy
2023-06-20 Downgrade Jefferies Buy → Hold
2022-04-22 Aggiornamento Piper Sandler Neutral → Overweight
2021-03-05 Iniziato H.C. Wainwright Buy
2020-07-29 Aggiornamento Oppenheimer Perform → Outperform
2020-07-24 Aggiornamento Jefferies Hold → Buy
2020-03-25 Downgrade Jefferies Buy → Hold
2020-03-24 Downgrade Oppenheimer Outperform → Perform
2020-03-24 Downgrade Piper Sandler Overweight → Neutral
2019-06-04 Iniziato Oppenheimer Outperform
2019-06-03 Iniziato Cowen Outperform
2019-06-03 Iniziato Jefferies Buy
2019-06-03 Iniziato Piper Jaffray Overweight
Mostra tutto

Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie

pulisher
Apr 23, 2025

Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News

Apr 23, 2025
pulisher
Apr 23, 2025

Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com

Apr 22, 2025
pulisher
Apr 22, 2025

A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com

Apr 22, 2025
pulisher
Apr 09, 2025

Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha

Apr 09, 2025
pulisher
Apr 05, 2025

Research Analysts Set Expectations for MIST Q1 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

MIST stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Reta - Asianet Newsable

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone flagging following CRL - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma says FDA declined to approve heart disorder therapy - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

FDA flags issues with Milestone’s new drug application - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone's heart rhythm nasal spray - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener

Mar 28, 2025
pulisher
Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025

Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):